<DOC>
	<DOCNO>NCT03060356</DOCNO>
	<brief_summary>This pilot study evaluate feasibility , safety , preliminary evidence efficacy intravenously administer , RNA electroporated autologous T cell express MET chimeric antigen receptor tandem TCRζ 4-1BB ( TCRζ /4-1BB ) co-stimulatory domain ( refer `` RNA CART-cMET '' ) patient advance melanoma breast carcinoma .</brief_summary>
	<brief_title>Autologous T Cells Expressing MET scFv CAR ( RNA CART-cMET )</brief_title>
	<detailed_description>This pilot study evaluate feasibility , safety , preliminary evidence efficacy intravenously administer , RNA electroporated autologous T cell express MET chimeric antigen receptor tandem TCRζ 4-1BB ( TCRζ /4-1BB ) co-stimulatory domain ( refer `` RNA CART-cMET '' ) patient advance melanoma breast carcinoma . Subjects treat IV administration RNA transduce anti-cMET CAR T cell total six dos 2 week period . Each dose 1x108 total T cell modify RNA anti-cMET CAR . All subject melanoma breast carcinoma arm receive 6 dos RNA CART-cMET cell , lymphodepleting chemotherapy administer prior cell infusion Cell number base total cell portion CAR expression depend transduction efficiency determine flow cytometry Based product release criterion , least 20 % total cell express anti-cMET CAR . Treatment limit toxicity ( TLT ) . Adverse event report begin start first dose RNA CART-cMET continue 4 month first infusion , another alternative therapy initiate , whichever occur early . Subjects continually reassess evidence acute cumulative toxicity .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<criteria>Unresectable histologically confirm stage III/IV melanoma metastatic locally advanced unresectable ER PR negative , HER2 neu nonamplified IHC and/or FISH breast carcinoma cMET expression ≥ 30 % tumor cell demonstrate immunohistochemistry analysis University Pennsylvania . MET IHC may perform tissue screen biopsy , archival slide metastatic deposit primary tumor . Punch biopsy percutaneous core biopsy offer obtain tissue require purpose . Patients must measureable disease define RECIST 1.1 criterion ; must CT scan chest , abdomen , pelvis within 1 month enrollment demonstrate measurable disease RECIST 1.1 criterion tumor one potentially biopsied resect correlative study Failure least one prior standard care therapy advance stage disease If previously treat form immunotherapy ( include agent target PD1 CTLA4 , oncolytic virus ) last administered treatment must least 2 week prior enrollment Males female patient age &gt; 18 year old Eastern Cooperative Oncology Group ( ECOG ) Clinical Performance Status 0 1 Adequate hematologic organ function define : WBC &gt; 3.0 ANC &gt; 1500 Plt &gt; 75,000 ( transfusion permit within 2 week achieve goal ) Hgb &gt; 9 g/dl ( transfusion permit achieve goal ) serum creatinine ≤ 1.5 time upper limit normal Total bilirubin ≤ 2times upper limit normal ALT AST ≤ 2 time upper limit normal Cardiac ejection fraction &gt; 40 % measure rest echocardiogram Women child bear potential must negative serum urine pregnancy test agree use appropriate contraception enrollment duration trial . Men must agree use appropriate contraception enrollment duration trial . Patients must provide write informed consent . Known metastatic tumor encase great vessel risk imminently cause spinal cord compression Known HIV1/HIV2 infection Known active infection Hepatitis B virus Hepatitis C virus Received experimental therapy within 30 day enrollment Pregnant woman lactate woman History alcohol abuse illicit drug use within 12 month enrollment Clinically significant comorbid disease underlie condition , include significant active infection , opinion PI subinvestigators , would contraindicate study therapy interfere interpretation study result Significant psychiatric disorder and/or reason Investigator 's opinion would jeopardize protocol compliance compromise patient 's ability give inform consent . Patients know allergy hypersensitivity study product excipients ( human serum albumin , DMSO , Dextran 40 ) . Patients clinically apparent arrhythmia , arrhythmias stable medical management within 2 week Screening/Enrollment visit . Having receive prior genetically manipulate Tcells prior clinical trial History autoimmune disease ( include limit : systemic lupus erythematosis , Sjogren syndrome , rheumatoid arthritis , psoriasis multiple sclerosis , inflammatory bowel disease etc ) . History immune related adverse event previous immunotherapy . Chronic use therapeutic anticoagulant coumadin , heparin , lovenox Symptomatic untreated CNS metastasis . Pts previously treat CNS metastasis eligible lesion radiographically/clinically stable without requirement steroid within 4 week prior treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>